drugset / Trial / NCT07629544
A Study of DA-302168S in Participants With Overweight/Obesity
Phase 3
Not yet recruiting
840 enrolled
Chendu DIAO Pharmaceutical Group CO., LTD.
Peking University People's Hospital · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study aimed at evaluating the efficacy, safety, and pharmacokinetic (PK) characteristics of DA-302168S tablets in overweight or obese participants in China.
Timeline
- Start
- 2026-06-27
- Primary completion
- 2027-07-09
- Completion
- 2027-10-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | DA-302168S | Small molecule | 10 mg | Oral |
| Comparator | DA-302168S | Small molecule | 20 mg | Oral |
Indications
No indication recorded.